"Patience is a Super Power" - "The Money is in the waiting"

Tuesday, March 11, 2025

Nvidia's interest and investment in Recursion Pharmaceuticals (RXRX) in 2025 could be a game changer for this small-cap!

 

 


Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that integrates advanced technologies across biology, chemistry, automation, data science, and engineering to decode complex biological systems. Here's an updated overview of the company's financials, partnerships, technological advancements, product pipeline, and other pertinent information:

Financial Overview

  • Cash Position: As of December 31, 2024, Recursion reported cash, cash equivalents, and restricted cash totaling $603.0 million, up from $401.4 million on the same date in 2023.ir.recursion.com

  • Revenue: The company achieved total revenue of $83 million for the fiscal year 2024, reflecting a strong financial performance.tipranks.com

  • Research and Development Expenses: R&D expenses were $74.6 million for Q3 2024, up from $70.0 million in Q3 2023, indicating continued investment in platform expansion and upgrades.globenewswire.com

  • Net Loss: The net loss for Q3 2024 was $95.8 million, compared to $93.0 million in Q3 2023, reflecting ongoing investments in research and development.globenewswire.com

Strategic Partnerships

  • NVIDIA: In July 2023, NVIDIA invested $50 million in Recursion to accelerate the development of AI foundation models for biology and chemistry. This collaboration leverages Recursion's extensive proprietary dataset and NVIDIA's cloud services, including the DGX™ Cloud and BioNeMo platform, to enhance drug discovery capabilities.en.wikipedia.org

  • Roche and Genentech: In December 2021, Recursion entered into a partnership with Roche and its subsidiary Genentech, potentially worth up to $12 billion, to advance therapies in neuroscience and other areas.en.wikipedia.org

  • Bayer: The company has a strategic collaboration with Bayer focusing on oncology research, building upon a previous partnership targeting fibrotic diseases.en.wikipedia.org

  • Exscientia Acquisition: In August 2024, Recursion acquired UK-based biotechnology company Exscientia for $688 million, adding a technology-enabled clinical pipeline and precision chemistry capabilities.globenewswire.com+1en.wikipedia.org+1

Technological Infrastructure

  • Recursion OS: The company's proprietary operating system integrates wet-lab and dry-lab biology experiments, enabling the generation of massive datasets to map and navigate complex biological relationships.sec.gov

  • BioHive-2 Supercomputer: In May 2024, Recursion completed BioHive-2, an NVIDIA-powered AI supercomputer comprising 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs. Ranked #35 in the TOP500 list of the world's most powerful supercomputers, BioHive-2 significantly enhances Recursion's computational capabilities, facilitating more efficient training of large-scale AI models.

Product Pipeline and Clinical Developments

  • REC-994: This experimental drug targets cerebral cavernous malformation (CCM), a rare brain-related condition. In a mid-stage study reported in September 2024, REC-994 demonstrated safety and tolerability. MRI-based data indicated that the highest dose reduced the number of lesions. However, improvements reported by patients or doctors were not observed at the end of the 12-month treatment period. Recursion plans to meet with the U.S. Food and Drug Administration to discuss further clinical studies.Reuters

  • Clinical Trial Outlook: Recursion anticipates seven clinical trial readouts over the next 18 months for its programs and approximately ten readouts collectively over the same period, including those from the Exscientia acquisition.globenewswire.com+1en.wikipedia.org+1

Intellectual Property

  • Patent Portfolio: As of February 2025, Recursion holds a total of 149 patents globally, with 58 granted. Notably, over 78% of these patents remain active. The majority are filed in the United States, followed by Europe and Canada.

Conclusion

Recursion Pharmaceuticals continues to leverage its robust financial position, strategic partnerships, and advanced technological infrastructure to pioneer AI-driven drug discovery and development. The company's expanding patent portfolio and active clinical pipeline underscore its commitment to transforming the pharmaceutical industry through innovative approaches to complex diseases.

Nvidia-backed Recursion's shares fall on mixed data for rare disorder drug
FaviconReuters

Monday, March 10, 2025

Is it time for Intel? Trading below it's moving averages, a cautious approach is probably in order.


 Intel Corporation (NASDAQ: INTC) is a leading multinational technology company renowned for designing and manufacturing microprocessors, chipsets, and various semiconductor components. Founded in 1968 and headquartered in Santa Clara, California, Intel has played a pivotal role in shaping the modern computing landscape.

Current Business Overview

Intel operates through several key segments:en.wikipedia.org

  • Client Computing Group (CCG): Focuses on personal computing products, including processors and chipsets for PCs and mobile devices.

  • Data Center Group (DCG): Provides server technologies and solutions for enterprise and cloud service providers.

  • Internet of Things Group (IoT): Delivers solutions for connecting devices across various industries.

  • Programmable Solutions Group (PSG): Offers programmable semiconductors, primarily Field-Programmable Gate Arrays (FPGAs).en.wikipedia.org

Financial Performance

Intel's recent financial performance has faced challenges:en.wikipedia.org+14apnews.com+14thetimes.co.uk+14

  • 2024 Financial Results: The company reported a revenue of $53.1 billion, a decrease from previous years, and a net loss of $19.2 billion.en.wikipedia.org

  • Cash Flow: In the fourth quarter of 2024, Intel generated $3.2 billion in cash from operations.intc.com

Strategic Initiatives and Future Focus

Intel has embarked on several strategic initiatives to regain its competitive edge:

  • Intel Foundry Services (IFS): Launched under the "IDM 2.0" strategy, IFS aims to offer manufacturing services to external clients. Notably, Nvidia and Broadcom are testing Intel's 18A process for their chip designs, potentially leading to significant contracts.welt.de+6barrons.com+6finance.yahoo.com+6

  • Manufacturing Expansion: Intel is investing in new fabrication plants (fabs) to enhance production capabilities:axios.com

    • Ohio Facility: Announced a $20 billion investment in a semiconductor factory in Licking County, Ohio. However, the timeline has been adjusted, with production facilities now expected to be completed in 2030 and 2031.axios.com+1marketwatch.com+1

    • Germany Facility: Plans for a €17 billion investment in Magdeburg, Germany, have been postponed, with production now slated for 2027.welt.de+2en.wikipedia.org+2de.wikipedia.org+2

    • Ireland Facility: Intel opened Fab 34 in Leixlip, Ireland, with a €17 billion investment, marking a significant expansion of its manufacturing footprint in Europe.en.wikipedia.org+1en.wikipedia.org+1

Recent Developments

  • Leadership Changes: In December 2024, CEO Pat Gelsinger retired amid financial challenges. David Zinsner and Michelle Johnston Holthaus were appointed interim co-CEOs as the company searches for a permanent leader.en.wikipedia.org+2apnews.com+2nypost.com+2

  • CHIPS and Science Act: Intel secured $8.5 billion in federal grants to build new fabs in Arizona and Ohio and to upgrade existing plants in Oregon and New Mexico, aligning with efforts to bolster domestic semiconductor manufacturing.en.wikipedia.org+1investors.com+1

Investment Considerations

Investors should weigh the following factors:

  • Competitive Landscape: Intel faces stiff competition from companies like TSMC and Nvidia. Its ability to attract clients like Nvidia and Broadcom to its foundry services could signal a positive shift.thetimes.co.uk+1barrons.com+1

  • Financial Health: The recent net loss and leadership changes highlight challenges. However, strategic investments and potential new contracts may pave the way for recovery.en.wikipedia.org+2apnews.com+2thetimes.co.uk+2

  • Manufacturing Expansion: Intel's substantial investments in new fabs demonstrate a commitment to enhancing production capabilities, though delays in some projects warrant attention.

In conclusion, while Intel faces challenges, its strategic initiatives and investments position it to potentially regain its competitive stature in the semiconductor industry.

​Intel Corp. (INTC)

$20.44
-$37.96(-65.00%)Past 5 years

As of March 10, 2025, Intel Corporation (NASDAQ: INTC) is trading at $20.44. Technical analysis indicates a predominantly bearish outlook:kavout.com
  • Moving Averages: The stock is trading below key moving averages, including the 50-day ($21.22) and 200-day ($24.15) simple moving averages, signaling potential downward momentum.barchart.com

  • Relative Strength Index (RSI): An RSI of 40.52% suggests the stock is nearing oversold conditions, which could precede a rebound.barchart.com

  • Trend Analysis: INTC is exhibiting weak performance within a declining trend channel over the medium to long term, indicating increasing pessimism among investors and a potential for further decline.investtech.com

Recent developments include reports that Nvidia and Broadcom are testing Intel's 18A manufacturing process for advanced AI-chip production, which could lead to significant manufacturing deals for Intel.markets.businessinsider.com

Given the current technical indicators and market conditions, it may be prudent to exercise caution and await more favorable signals before considering an investment in Intel's stock.

Intel's Strategic Moves Amidst Industry Challenges

Sunday, March 9, 2025

From Google's Waymo, to Amazon's Zooks and Tesla's future Robo Taxi intentions, suppliers to these companies could see great gains!

 


Here is a ranked list of publicly traded companies supplying either Waymo or Tesla with technology, software, or components for their self-driving efforts. The ranking is based on influence and technological impact in the self-driving space.

Most Influential Public Companies Supplying Waymo & Tesla:

  1. NVIDIA (NVDA) – Provides AI computing platforms critical for autonomous driving.
  2. Intel (INTC) – Owns Mobileye, a leader in vision-based autonomous driving tech.
  3. Samsung Electronics (SSNLF, KRX: 005930) – Supplies Tesla’s Hardware 4 (HW4) self-driving chips.
  4. Magna International (MGA) – Supplies vehicle systems and components for self-driving.
  5. Panasonic (PCRFY, TYO: 6752) – Tesla’s primary battery supplier, key for EV autonomy.
  6. Bosch (Privately Held, but key supplier, included for reference) – Provides key sensors for autonomous driving.
  7. Continental AG (CTTAY, ETR: CON) – Develops electronic systems and sensors used in AVs.
  8. Aptiv (APTV) – Leader in autonomous driving safety and sensor tech.
  9. Luminar Technologies (LAZR) – Lidar sensor supplier, vital for perception in AVs.
  10. Zeekr (Geely's Subsidiary, HK: 0175 via parent company Geely Auto) – Partnered with Waymo for robotaxi production.

These publicly traded companies are among the most influential in advancing Tesla's and Waymo’s self-driving technology. Would you like a deeper look into any of these?

---------------------------------------------------------------------------------------------------------

Several of the previously mentioned publicly traded companies supply not only Waymo and Tesla but also other players in the autonomous vehicle (AV) and robotaxi market, including Zoox (an Amazon subsidiary) and others. Here's an overview:​

1. NVIDIA (NVDA):

  • Mobileye: In November 2021, NVIDIA partnered with Luminar Technologies to enhance lidar capabilities for autonomous vehicles.

2. Intel (INTC):

  • Mobileye: An Intel subsidiary, Mobileye has collaborated with various automakers, including BMW, Nissan, and Volkswagen, to integrate its autonomous driving technologies.en.wikipedia.org+1en.wikipedia.org+1

3. Luminar Technologies (LAZR):

4. Aurora Innovation (AUR):

5. Hyundai Motor Company (HYMTF):

  • Avride: In March 2025, Hyundai partnered with self-driving technology startup Avride to expand its robotaxi fleet, deploying 100 Hyundai Ioniq 5 vehicles equipped with Avride's autonomous technology.en.wikipedia.org+2theverge.com+2reuters.com+2

6. Magna International (MGA):

  • General Motors (GM): Magna has been involved in developing technologies pertinent to autonomous driving and has collaborated with companies like GM on self-driving initiatives.

7. Bosch:

  • Daimler (Mercedes-Benz): Bosch has partnered with Daimler to develop autonomous driving systems, particularly for urban environments.

8. Continental AG (CTTAY):

  • Various Automakers: Continental supplies sensors and control units essential for autonomous driving functionalities to multiple automakers.en.wikipedia.org

9. Aptiv (APTV):

10. Mobileye (MBLY): - Lyft: Mobileye has partnered with Lyft to integrate its self-driving technology into Lyft's ride-hailing platform, aiming to deploy robotaxis by 2026.

These collaborations highlight the interconnected ecosystem of suppliers and manufacturers working together to advance autonomous driving technologies across various platforms and services.

----------------------------------------------------------------------------------------------------------------

Trump Tariffs impact on supply chains for AVs

The recent imposition of new U.S. tariffs on imports from Mexico, Canada, and China is poised to significantly impact companies supplying components and technology to autonomous vehicle (AV) manufacturers like Waymo, Tesla, and Zoox. Here's an analysis of the potential effects on these suppliers:​

1. Increased Operational Costs:

  • NVIDIA (NVDA): As a supplier of advanced computing platforms for AVs, NVIDIA relies on a global supply chain. Tariffs on Chinese imports, including electronic components, could escalate production costs, potentially leading to higher prices for their products.

  • Intel (INTC): Through its subsidiary Mobileye, Intel provides vision-based systems for autonomous driving. Tariffs affecting semiconductor components from China may increase manufacturing expenses, influencing the pricing of their technologies.

  • Samsung Electronics (SSNLF): Supplying processors for Tesla's self-driving systems, Samsung's production costs could rise due to tariffs on Chinese electronic parts, potentially affecting their profit margins.

2. Disruption of Supply Chains:

  • Magna International (MGA): As a global automotive supplier, Magna's operations span multiple countries. Tariffs on imports from Mexico and Canada could disrupt their supply chains, leading to delays and increased costs in delivering components to AV manufacturers.

  • Panasonic (PCRFY): Partnering with Tesla for battery production, Panasonic's supply chain might be affected by tariffs on raw materials or components sourced from China, potentially increasing production costs.

3. Strategic Reassessment:

  • Bosch: Providing sensors and components for autonomous vehicles, Bosch may need to reassess its sourcing and manufacturing strategies to mitigate the impact of tariffs, possibly leading to increased operational costs.

  • Continental AG (CTTAY): As a supplier of electronic systems and sensors, Continental might face higher costs due to tariffs on Chinese imports, prompting a reevaluation of their supply chain strategies.

4. Market Competitiveness:

  • Aptiv (APTV): Specializing in autonomous driving technologies, Aptiv could experience increased costs due to tariffs on electronic components from China, potentially affecting their competitiveness in the AV market.

  • Luminar Technologies (LAZR): Supplying lidar sensors essential for AVs, Luminar might face higher production costs if components are sourced from tariff-affected regions, influencing their pricing strategies.

5. Regulatory and Compliance Challenges:

  • Zeekr (via Geely Auto, HK: 0175): Partnering with Waymo for robotaxi production, Zeekr could encounter increased costs due to tariffs on Chinese-made vehicles and components, potentially affecting their collaboration dynamics.en.wikipedia.org

The new U.S. tariffs are likely to increase operational costs, disrupt supply chains, and necessitate strategic adjustments for these suppliers. These changes could lead to higher prices for AV manufacturers and, ultimately, consumers. Companies may need to explore alternative sourcing options, renegotiate supplier contracts, or absorb additional costs to maintain their market positions.

-------------------------------------------------------------------------------------------------------------

Bottom Line for Investors in These Companies:

The new U.S. tariffs will create short-term headwinds for companies supplying technology and components to Waymo, Tesla, Zoox, and other AV makers. However, the long-term growth potential of autonomous driving and electric vehicles (EVs) remains intact. Here’s a breakdown of the key investment takeaways:


1. Companies Likely to Feel the Most Pressure (Short-Term Risks)

  • Luminar Technologies (LAZR) → Heavy reliance on Chinese-manufactured lidar components could raise costs.
  • Zeekr (via Geely Auto, HK: 0175) → Tariffs on China-made vehicles/components may impact partnerships like Waymo’s robotaxis.
  • Magna International (MGA) & Panasonic (PCRFY) → Cross-border tariffs on vehicle components from Mexico/Canada may increase supply chain costs.

📉 Investor Outlook: These stocks could see short-term volatility as they navigate higher costs and supply chain disruptions.


2. Companies That Will Need to Adapt (Neutral to Slightly Negative)

  • Intel (INTC) & NVIDIA (NVDA) → If China retaliates, semiconductor supply chains may be affected.
  • Bosch & Continental AG (CTTAY) → Higher tariffs could make AV components pricier, impacting profit margins.
  • Aptiv (APTV) → Autonomous vehicle technology may become more expensive to produce.

📊 Investor Outlook: These companies have strong global supply chains and could offset costs over time. Look for dips to buy long-term.


3. Companies That Could Benefit (Long-Term Winners)

  • Samsung (SSNLF) & NVIDIA (NVDA) → If U.S. companies shift away from Chinese suppliers, these firms could gain more business.
  • Mobileye (Owned by Intel - INTC) → U.S. automakers may look for domestic AV technology, favoring Mobileye over Chinese alternatives.
  • Aptiv (APTV) → If the U.S. increases domestic EV/AV production, Aptiv could gain new contracts.

🚀 Investor Outlook: These companies could emerge stronger as the U.S. onshores more production.


Final Verdict for Investors

Long-Term Investors: Buy on dips for NVIDIA (NVDA), Intel (INTC), Samsung (SSNLF), and Mobileye (via INTC)—these are essential for AV and AI growth.
⚠️ Short-Term Traders: Expect volatility in Luminar (LAZR), Magna (MGA), and Geely (0175) due to direct tariff impacts.
🏆 Winners: Companies that shift supply chains away from China or dominate U.S. AV tech (Mobileye, NVIDIA, Aptiv) stand to benefit in the long run.

(Prepared with ChatGPT 4o)

Friday, March 7, 2025

What's up with UiPath, it's Robotics Automation and it's recent push into healthcare?

 


Below is a comprehensive investment and business report on UiPath 

NYSE:PATH 

Please note that all figures and information are based on publicly available data as of the most recent disclosures; for the most up-to-date figures, consult UiPath’s SEC filings, official press releases, and reputable financial news outlets.


1. Company Overview

UiPath is a leading enterprise automation software company, specializing in Robotic Process Automation (RPA), AI-driven document understanding, and, more recently, “agentic automation.” Founded in 2005 in Romania, UiPath has since expanded globally, serving a wide range of industries. The company went public on the New York Stock Exchange in April 2021 under the ticker PATH.

Core Value Proposition

  • Provides automation solutions (software “robots”) that mimic human actions for repetitive digital tasks.
  • Integrates AI/ML to enable more complex workflows, including document understanding, natural language processing, and generative AI.
  • Offers an end-to-end platform for discovery, building, managing, running, and engaging with automation solutions at scale.

2. Recent Developments & Strategic Highlights

2.1 New Global Consulting Agreement with a Major EMR Platform

  • Announcement (2025): UiPath negotiated a global consulting agreement with a major Electronic Medical Records (EMR) platform to accelerate professional services for healthcare organizations in 16 new countries (e.g., Australia, France, Germany, Italy, Singapore, Sweden, etc.).
  • Impact:
    • Increases UiPath’s global footprint, particularly in the healthcare vertical—a large, growing market.
    • Shortens the access and implementation timelines for clients (from weeks to days).
    • Reinforces UiPath’s positioning in agentic automation—using large language models (LLMs) and generative AI (GenAI) for autonomous workflows in complex, regulated environments such as healthcare.

2.2 Expansion into “Agentic AI” and Generative AI

  • UiPath is emphasizing “agentic” automation—where software agents can perceive, reason, and take actions autonomously.
  • Aligns with the broader enterprise AI trend, positioning UiPath as more than just an RPA vendor.

2.3 Other Key Partnerships & Contracts

  • Microsoft Collaboration: Integration with Microsoft Power Platform, Azure ML, and other Azure AI services to enhance cross-platform automation.
  • AWS Partnership: UiPath robots running on AWS to serve large enterprise customers.
  • SAP Endorsed App: UiPath is an SAP Endorsed App, which helps it sell automation solutions more effectively into the SAP install base.
  • ServiceNow & Salesforce Integrations: Bolstering UiPath’s ability to automate workflows involving customer service and CRM data.

3. Financial Performance

Note: Figures below are approximate and for illustrative purposes, based on the latest reported fiscal year or quarterly release. Always check the most recent 10-Q/10-K for updated data.

3.1 Revenue & Growth

  • Revenue: UiPath reported revenues in the range of $1.0–$1.1 billion on an annualized basis in its recent filings. Growth rates have varied quarter to quarter but have typically shown double-digit percentages year-over-year.
  • Annualized Renewal Run-Rate (ARR): Often cited by UiPath as a key metric, has shown steady increases, reflecting strong customer retention and expansions.

3.2 Profitability & Margins

  • Gross Margins: Typically strong for software companies (70%–80%+). UiPath reinvests heavily in R&D and market expansion, so operating margins can fluctuate.
  • Net Income: UiPath has posted occasional net losses, reflecting investment in sales, marketing, and acquisitions. The company has signaled a path toward improved profitability through cost optimization and efficiencies in its go-to-market strategy.

3.3 Cash Position & Balance Sheet

  • UiPath had a strong cash and short-term investments position, historically in the range of $1.5–$2.0 billion. This ample liquidity provides flexibility to fund R&D, potential acquisitions, and global expansion.
  • Low debt levels relative to its cash reserves, which generally de-risks the balance sheet.

4. Institutional Investors & Ownership

UiPath’s major institutional investors have included:

  • ARK Investment Management (Cathie Wood)
  • BlackRock, Inc.
  • Morgan Stanley
  • Vanguard Group

These institutions often rebalance their positions based on market conditions and investment theses; consult the latest 13F filings to see current stakes.


5. Key Customers & Industry Verticals

5.1 Enterprise & Mid-Market Customers

  • UiPath has historically attracted Global 2000 companies, with a strong presence in financial services, telecom, and manufacturing.
  • The healthcare sector is becoming a key target, especially with the recent EMR agreement.

5.2 Notable Clients

  • Large banks (e.g., JP Morgan, Bank of America—though specifics may vary by deployment).
  • Healthcare organizations (e.g., major hospital systems using UiPath for claims processing, patient data management).
  • Manufacturing and logistics firms deploying UiPath for supply chain and back-office automation.
  • Government agencies in various regions for document processing and compliance workflows.

6. Growth Drivers & Prospects

6.1 Continuing Global RPA Adoption

  • The RPA market is projected to grow in the mid-to-high double digits annually over the next few years. Enterprises continue to automate back-office tasks, fueling demand for UiPath’s core offerings.

6.2 AI & “Agentic” Automation

  • There is a shift from simple task automation to intelligent, end-to-end workflows leveraging machine learning (ML) and generative AI.
  • UiPath’s AI Center and new emphasis on “agentic automation” could differentiate it from competitors, attracting enterprise clients looking for advanced, autonomous solutions.

6.3 Industry-Specific Solutions

  • Verticals like healthcare, financial services, and public sector present large growth opportunities.
  • The new EMR agreement opens additional healthcare markets—16 new countries—for professional services and automation deployments.

6.4 Ecosystem & Integration

  • Partnerships with SAP, ServiceNow, Salesforce, Microsoft, and Amazon Web Services expand UiPath’s ecosystem.
  • Pre-built integrations reduce friction for customers adopting UiPath’s automation platform.

7. Competitive Landscape

  1. Automation Anywhere

    • A direct RPA competitor with a cloud-native platform.
    • Similar enterprise focus but historically smaller than UiPath in overall market share.
  2. Blue Prism (now part of SS&C)

    • Another RPA pioneer, strong in Europe.
    • More traditional approach to RPA, though it is now integrating AI components post-acquisition by SS&C.
  3. Microsoft Power Automate

    • Part of the Microsoft ecosystem.
    • Less feature-rich in pure-play RPA than UiPath, but deeply integrated with Office 365 and other Microsoft products, making it a formidable competitor for some SMB and mid-market use cases.
  4. Appian

    • Offers a low-code platform with automation features.
    • Focuses on end-to-end process automation, including business process management and RPA.
  5. IBM / Oracle / Salesforce

    • Large enterprise software vendors offering automation modules that can overlap with certain UiPath capabilities.
    • Typically bigger product portfolios but not purely focused on RPA/automation.

8. Opportunities & Risks

8.1 Opportunities

  • Healthcare Expansion: The new EMR consulting agreement could catalyze growth in a massive global healthcare market.
  • AI & Generative Automation: Being at the forefront of agentic AI could differentiate UiPath, opening up new enterprise deals that go beyond standard RPA.
  • Cross-Selling & Upselling: Existing RPA clients can be sold additional AI modules, document understanding, or expanded service engagements.

8.2 Risks

  • Competition: The market is crowded. Tech giants and other specialized RPA/AI vendors challenge UiPath’s pricing and market share.
  • Economic Slowdowns: Enterprise software budgets can contract if macro conditions worsen, potentially delaying automation projects.
  • Integration & Complexity: As automation and AI become more intertwined, implementation complexity could rise. Companies may opt for simpler, lower-cost solutions if UiPath’s platform is perceived as too costly or complex.
  • Regulatory / Data Privacy: In healthcare and finance, privacy regulations are stringent, requiring robust compliance frameworks.

9. Conclusion & Investment Perspective

Overall, UiPath (PATH) stands out as a leader in the enterprise automation and AI space. Its:

  • Strong balance sheet and ample cash provide flexibility.
  • Healthcare expansion via the global EMR agreement showcases sector-specific growth potential.
  • Increasing focus on AI (“agentic automation”) aligns UiPath with cutting-edge automation trends and enterprise demand.

For long-term investors who believe in the sustained growth of enterprise automation and AI, UiPath’s combination of market leadership, large addressable market, and evolving AI-driven product strategy presents an attractive thesis. However, potential investors should monitor:

  • Quarterly execution (ARR, net new customers, partner expansions).
  • Competition from tech giants and specialized RPA vendors.
  • Path to profitability, as the company continues to balance growth with controlling costs.

Disclaimer: This report is for informational purposes only and does not constitute financial or investment advice. Always conduct your own due diligence and consult a qualified financial advisor before making any investment decisions.


Ed Note:

We are long UiPath stock!

References & Additional Resources

Monday, March 3, 2025

Commodities are often overlooked in a young investors portfolio. They should not be!


 Investors looking for stability and lucrative returns over the next two years, I would rank these natural resources in the following order, considering supply-demand dynamics, geopolitical risks, energy transition trends, and industrial importance:

Ed Note: 

We are currently invested in companies producing 5 of these commodities.

1. Uranium

  • Bullish Case: Nuclear energy is experiencing a renaissance, with increasing global support for clean energy. Supply is constrained, and demand is rising with new reactor projects and small modular reactors (SMRs).
  • Key Players: Cameco (CCJ), Kazatomprom, NexGen Energy (NXE).
  • Risk: Some policy risks if governments shift focus.

2. Copper

  • Bullish Case: Essential for electrification (EVs, power grids, renewables), and long-term supply deficits are expected due to lack of new mines. Prices have remained strong.
  • Key Players: Freeport-McMoRan (FCX), Southern Copper (SCCO), BHP.
  • Risk: Short-term recession could dampen demand.

3. Oil

  • Bullish Case: Despite the energy transition, oil demand remains strong. OPEC+ supply cuts and geopolitical risks (Middle East conflicts, Russia sanctions) keep prices elevated.
  • Key Players: ExxonMobil (XOM), Chevron (CVX), Saudi Aramco.
  • Risk: Demand destruction if global economic slowdown occurs.

4. Natural Gas

  • Bullish Case: Europe's pivot away from Russian gas, LNG export growth (U.S. to Europe/Asia), and continued reliance on gas as a transition fuel.
  • Key Players: Cheniere Energy (LNG), EQT Corp (EQT).
  • Risk: Overproduction could lower prices, mild winters reduce demand.

5. Lithium

  • Bullish Case: EV demand remains strong, but overproduction has led to price volatility. Long-term supply chain constraints could tighten the market again.
  • Key Players: Albemarle (ALB), SQM, Lithium Americas (LAC).
  • Risk: High volatility, price declines if demand slows.

6. Rare Earths

  • Bullish Case: Critical for defense, electronics, and EVs. China dominates supply, but Western nations are ramping up production. Supply chain security remains a priority.
  • Key Players: MP Materials (MP), Lynas Rare Earths (LYC).
  • Risk: Geopolitical uncertainty; rare earth processing is complex.

7. Nickel

  • Bullish Case: Needed for EV batteries and stainless steel. Supply disruptions in Indonesia and Russia could support prices.
  • Key Players: Vale (VALE), Norilsk Nickel, BHP.
  • Risk: EV battery chemistry shifting away from high-nickel designs.

8. Gold

  • Bullish Case: Inflation hedge, central bank demand, and safe-haven asset during global uncertainties.
  • Key Players: Barrick Gold (GOLD), Newmont (NEM).
  • Risk: Interest rate cuts could impact returns.

9. Water

  • Bullish Case: Scarcity makes it an essential resource. Water infrastructure, desalination, and privatization could drive investment.
  • Key Players: American Water Works (AWK), Veolia (VEOEY).
  • Risk: Regulatory constraints on private water ownership.

10. Potash

  • Bullish Case: Fertilizer demand is steady due to global food security concerns.
  • Key Players: Nutrien (NTR), Mosaic (MOS).
  • Risk: Agricultural cycles can impact demand.
  • .

Final Thoughts:

For a balanced, stable, and profitable investment in natural resources over the next two years, Uranium, Copper, and Oil seem the strongest plays due to demand-supply imbalances and global energy trends. Natural Gas and Lithium are also good, but face short-term price volatility. Rare Earths and Nickel are critical, but geopolitical risks and tech advancements could impact pricing. Gold, Water, and Potash are more defensive but lack aggressive upside.